Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, has announced the first results from a collaboration with Insilico Medicine, a clinical-stage biotechnology company driven by...

For too long, regulatory teams have become bogged down by protracted reviews of the regulatory implications of each new product change, with potential risk to drug availability until these have been assessed and actions...